Postvaccination Symptoms After a Third Dose of MRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease: Results From CORALE-IBD
Overview
Authors
Affiliations
Background: The safety of a third dose of SARS-CoV-2 mRNA vaccination in patients with inflammatory bowel disease is unknown.
Methods: We compared symptoms following a third SARS-CoV-2 mRNA vaccine dose with symptoms after the second dose in IBD.
Results: The study group included 594 patients (70% female, 58% BNT162b2). Overall, 41% reported symptoms after a third dose. Symptom frequency and severity were lower after the third dose relative to the second dose for every organ system, except for gastrointestinal symptoms which were marginally worse.
Conclusion: The frequency and severity of symptoms after a third mRNA vaccine dose are generally similar or milder than after a second dose for most organ systems.
Schell T, Caldera F Gastroenterol Hepatol (N Y). 2024; 20(2):88-97.
PMID: 38414911 PMC: 10895915.
Caldera F, Rolak S, Farraye F, Necela B, Cogen D, Zona E Clin Transl Gastroenterol. 2024; 15(4):e00688.
PMID: 38349178 PMC: 11042770. DOI: 10.14309/ctg.0000000000000688.
Lee Y, Li D, Mujukian A, Debbas P, Hampton M, Mengesha E Inflamm Bowel Dis. 2023; 30(8):1430-1434.
PMID: 37773982 PMC: 11291623. DOI: 10.1093/ibd/izad198.
The 2023 Impact of Inflammatory Bowel Disease in Canada: COVID-19 and IBD.
Kaplan G, Kuenzig M, Windsor J, Bernstein C, Bitton A, Coward S J Can Assoc Gastroenterol. 2023; 6(Suppl 2):S76-S82.
PMID: 37674494 PMC: 10478806. DOI: 10.1093/jcag/gwad019.
Tsipotis E, Maremanda A, Zeiser L, Connolly C, Sharma S, Dudley-Brown S Medicina (Kaunas). 2023; 59(8).
PMID: 37629777 PMC: 10456461. DOI: 10.3390/medicina59081487.